🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseGLP-1 hepatoprotection — direct vs indirect mechanisms Page 3

GLP-1 hepatoprotection — direct vs indirect mechanisms

MASHdoc_SA Sun, Jun 7, 2026 at 4:05 PM 16 replies 402 viewsPage 3 of 4
greg_boulder
Member
345
1,567
Jul 2024
Boulder, CO
Jun 7, 2026 at 8:47 PM#11
SleepDoc_PDX said:
Receptor pharmacology relevant to the pharmacology: semaglutide is a GLP-1R agonist with a C-18 fatty acid chain that enables albumin binding (>99%),…

Thank you for spelling out the reasoning rather than just the conclusion. Sending this to two other people who asked me the same thing last week.

32 5denise_HTX, raj_cambridge, ingrid_STO and 29 others
Reply Quote Save Share Report
Dr.PeteFamMed
Senior Member
2,012
9,234
Jan 2024
Minneapolis, MN
Jun 7, 2026 at 11:32 PM#12

From the other side of the consultation, briefly. Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third retelling.

Last edited: Jun 8, 2026 at 12:32 AM
33 6tommy_boulder, hyun_seoul, jim_asheville and 30 others
Reply Quote Save Share Report
TrialNerd_Beth
Senior Member
2,345
11,234
Jan 2024
Bethesda, MD
Jun 8, 2026 at 2:16 AM#13
paige_pharma said:
Semaglutide structural biology relevant to the pharmacology: semaglutide is a 31-amino acid peptide with 94% homology to native GLP-1(7-36).

Pushing back on paige_pharma here. Not convinced. The evidence being cited is consistent with the conclusion and also consistent with two other conclusions nobody has ruled out.

Last edited: Jun 8, 2026 at 6:16 AM
34 7TomTeleRx, DoseLogDan, SleepFixSam and 31 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
VendorMark
Senior Member
3,456
14,567
Jan 2024
Texas
Online
Jun 8, 2026 at 5:01 AM#14

The figures, for anyone assembling their own picture. Say what you would expect to see if you were wrong, before you look. It is a small discipline and it changes what you notice.

35 8Dr.PeteFamMed, claudia_zurich, nancy_portland and 32 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Jun 8, 2026 at 7:45 AM#15

Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source. Tagging this one for the weekly digest.

Last edited: Jun 8, 2026 at 9:45 AM
36 9PurityPaulOR, MaxMetOK, MounjBrad and 33 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
MASH resolution without worsening fibrosis — endpoint analysis11 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register